Pfizer, Alphabet And This ETF: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management said Pfizer Inc. (NYSE: PFE) has a 3.8% yield and is trading at
Pfizer, Valneva Discontinue Certain Trial Sites For Phase 3 Study Of Lyme Disease Vaccine Candidate
Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announce that Pfizer, as the study sponsor, will discontinue a significant percentage of participants in the…
Pfizer And Valneva Announce That Pfizer, As The Study Sponsor, Has Decided To Discontinue A Significant Percentage Of Participants In The U.S. Who Had Been Enrolled In The Valor Phase 3 Study, Due To Violations Of Good Clinical Practice
The study is investigating the efficacy, safety, and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15.
These study participants, representing approximately half of the total recruited
Black Professionals Working In Public Cannabis Companies To Create A More Equitable Industry
Troy Datcher is CEO & chairman of The Parent Company (OTCQX: GRAMF) who made history in August 2021 when
Pfizer Releases Interim Update On PARP Inhibitor Combo Therapy For Prostate Cancer, Secures FDA Priority Review
Pfizer Inc (NYSE:PFE) announced results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) in 1,106…
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among the alternatives to create value. In addition, cannabis companies might look at risk mitigation as an alternative to achieve higher quality and prevent losses.
Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program
https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna
Daiwa Capital Upgrades Pfizer to Outperform, Announces $51 Price Target
Daiwa Capital analyst Narumi Nakagiri upgrades Pfizer (NYSE:PFE) from Neutral to Outperform and announces $51 price target.
Barron’s Top Weekend Stock Picks: Apple, Disney, Pfizer And Tesla’s Price Cuts Are Leading To Growth
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.